TM
NEXT GENERATION DRUGS TO TREAT
AUTOIMMUNE, CHRONIC INFLAMMATORY DISEASE
AND CANCER
ABOUT SFA THERAPEUTICS
Our journey began with a deep fascination for the intricate world of the human gut bacterial ecosystem and its profound impact on overall well-being. Our founders, a team of passionate researchers and healthcare professionals, were intrigued by the pivotal role this complex microbiota plays in maintaining human health. The various bacteria produce a complex, yet synergistic, set of metabolites in our intestines that exhibit profound, wide-ranging effects on metabolism and immune function.
​​
​​
​​
​As we delved deeper into the science, we uncovered the potential of these biosynthetic molecules, that mimic naturally occurring substances, in addressing a variety of health challenges, from autoimmune disease to metabolic disorders. We were particularly captivated by how these simple organic compounds could influence complex cellular processes and serve as a communication bridge between our gut microbiome and immune system.
​
​​
​​​​​
We discovered ways of increasing the selectivity and specifictiy of our biosynthetics after elucidating pathways and targets. We have developed a platform technology that allows us to target specific diseases and create disease-specific drugs. ​​​​Our technology platform represents a convergence of microbial science, pharmaceutical innovation, and precision medicine, offering new hope for patients across multiple therapeutic areas.
​
​Join us on this exciting journey as we work towards a healthier future, one molecule at a time.
INNOVATIVE DRUGS
PREDICTABLE OUTCOMES
Innovative Oral Formulations Allow for Consistent Clinical Outcomes
PATHWAY TARGETED
Small Molecules that Interact Selectively with Disease-specific Targets and Maintain Immune Homeostasis
SUPERIOR
SAFETY
Small Molecules that Mimic Endogenous Substances found in the Human Body
HIGHLY EFFICACIOUS
Boosts Anti-inlammatory IL-10 Expression and Downregulates Pro-inflammatory Cytokines
LOW COST
Seamless Manufacturing Process
POWERFUL and NOVEL PLATFORM
1
2
3
4
TARGETED BIOSYNTHESIS
PLATFORM
5
AUTOIMMUNE DISEASES
PSORIASIS, RHEUMATOID ARTHRITIS,
UVEITIS AND BULLOUS PEMPHIGOID
CANCERS
HEPATOCELLULAR CARCINOMA, PANCREATIC CANCER AND MYELOID LEUKEMIAS
INFECTIOUS DISEASES
POST-VIRAL INFLAMMATORY COMPLICATIONS​
LIVER DISEASES
FIBROSIS AND MASH/NASH ​
ANTI-INFLAMMATORY ADJUVANTS
CAR-T THERAPIES
OUR PARTNERS
SFA THERAPEUTICS
IS A
VENTURE CAPITAL BACKED CLINICAL-STAGE BIOTECHNOLOGY COMPANY
SFA THERAPEUTICS IN THE NEWS
JENKINTOWN, Pa., May 17, 2024 BUSINESS WIRE -- Article by SFA Therapeutics Founders Featured in Drug Target Review
JENKINTOWN, Pa., May 2, 2024 PRNewswire -- SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer
JENKINTOWN, Pa., February 29, 2024 BUSINESS WIRE -- Ben Franklin Healthcare Investments: 1.3 Million in Four Companies
JENKINTOWN, Pa., December 7, 2023 BUSINESS WIRE -- SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent
JENKINTOWN, Pa., August 14, 2023 BUSINESS WIRE -- SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis
JENKINTOWN, Pa., August 14, 2023 BUSINESS WIRE -- SFA Therapeutics Founders Publish an Article Titled “Short‑chain fatty acids in cancer pathogenesis”